Showing results (181-190 of 203) with videos related to

Sort By:
Pageof 21
BMJ Open|December 18, 2019
Chinese multicentre prospective registry of breast cancer patient-reported outcome-reconstruction and oncoplastic cohort (PRO-ROC): a study protocolLun Li, Benlong Yang, Hongyuan Li, et al.
Cancer Pathogenesis and Therapy|April 4, 2025
Breast cancer risk associated with <i>BRCA1</i> and <i>BRCA2</i> pathogenic variants in the Eastern Chinese populationSanjian Yu, Xia Qiu, Zezhou Wang, et al.
Health and Quality of Life Outcomes|March 25, 2016
Health-related quality of life of postmenopausal Chinese women with hormone receptor-positive early breast cancer during treatment with adjuvant aromatase inhibitors: a prospective, multicenter, non-interventional studyAyong Cao, Jin Zhang, Xiaoan Liu, et al.
British Journal of Cancer|June 21, 2024
QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trialWenjia Zuo, Zhonghua Wang, Jun Qian, et al.
JAMA Oncology|October 25, 2019
Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical TrialZhimin Shao, Da Pang, Hongjian Yang, et al.
Lancet (London, England)|December 3, 2016
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trialJohn F R Robertson, Igor M Bondarenko, Ekaterina Trishkina, et al.
The Lancet. Oncology|January 30, 2016
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trialNadia Harbeck, Chiun-Sheng Huang, Sara Hurvitz, et al.
The Lancet. Oncology|June 21, 2015
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trialSara A Hurvitz, Fabrice Andre, Zefei Jiang, et al.
Plos One|May 1, 2015
Identification of a comprehensive spectrum of genetic factors for hereditary breast cancer in a Chinese population by next-generation sequencingXiaochen Yang, Jiong Wu, Jingsong Lu, et al.
Breast Cancer Research and Treatment|December 2, 2022
Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II studyBinghe Xu, Tao Sun, Yanxia Shi, et al.
Pageof 21